Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries-Reference-Cited by-同舟云学术

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries

Published:2022-05-16 Issue:5 Volume:28 Page:713-719
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Lehtinen Anna‐Elina¹,Baghaei Fariba²,Astermark Jan³^ORCID,Holme Pål André⁴

Affiliation:

1. Coagulation Disorders Unit, Department of Haematology Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland

2. Coagulation Centre, Department of Medicine/Section of Haematology and Coagulation Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden

3. Institution for Translational Medicine Lund University and Department for Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö Sweden

4. Department of Haematology Oslo University Hospital and Institute of Clinical Medicine, University of Oslo Oslo Norway

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14585

Reference36 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations

3. WFH Guidelines for the Management of Hemophilia, 3rd edition

4. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIF c

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18

2. Development and evaluation of a bivalent vaccine based on recombinant newcastle disease virus expressing infectious bursal disease virus VP2L-CH3-CH4 in SPF chickens;Veterinary Microbiology;2024-01

3. Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery;Haemophilia;2023-12-27

4. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis;Research and Practice in Thrombosis and Haemostasis;2023-08

5. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries;Advances in Therapy;2023-06-23